Weekly Research Analysts’ Ratings Changes for Quantum Biopharma (QNTM)

Several analysts have recently updated their ratings and price targets for Quantum Biopharma (NASDAQ: QNTM):

• 12/2/2025 – Quantum Biopharma had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 11/28/2025 – Quantum Biopharma was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating.
• 11/26/2025 – Quantum Biopharma had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 11/20/2025 – Quantum Biopharma had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 11/1/2025 – Quantum Biopharma was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating.

Quantum Biopharma Ltd. is a biotechnology pharmaceutical research and development company, which focuses on the cultivation, process, and sale of medical cannabis. It operates through the Biotechnology and Strategic Investments segments. The Biotechnology segment is involved in the research and development of the company’s three drug candidates consisting of FSD-PEA, Lucid-PSYCH, and Lucid-MS.